Ruili Wang

发表

Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study

M. Hudgens, J. Eron, D. Wohl, 2012, Antimicrobial Agents and Chemotherapy.

Tenofovir/Emtricitabine Metabolites and Endogenous Nucleotide Exposures are associated with p16INK4a Expression in Subjects on Combination Therapy

M. Hudgens, N. Sharpless, C. Torrice, 2016, Antiviral therapy.

Dose Frequency Ranging Pharmacokinetic Study of Tenofovir-Emtricitabine After Directly Observed Dosing in Healthy Volunteers to Establish Adherence Benchmarks (HPTN 066).

K. Mayer, E. Fuchs, C. Hendrix, 2016, AIDS research and human retroviruses.

Protein Binding of Lopinavir and Ritonavir During 4 Phases of Pregnancy: Implications for Treatment Guidelines

M. Hudgens, A. Kashuba, A. Jenkins, 2013, Journal of acquired immune deficiency syndromes.

Pharmacokinetics of Tenofovir following Intravaginal and Intrarectal Administration of Tenofovir Gel to Rhesus Macaques

Joseph P. Romano, P. Allen, J. Nuttall, 2011, Antimicrobial Agents and Chemotherapy.

Effect of HIV Infection and Menopause Status on Raltegravir Pharmacokinetics in the Blood and Genital Tract

A. Kashuba, N. White, K. Patterson, 2015, Antiviral therapy.

Title: The Pharmacokinetics of Tenofovir Following Intravaginal and Intrarectal

P. Allen, J. Nuttall, A. Kashuba, 2011 .

Pharmacokinetics of two common antiretroviral regimens in older HIV‐infected patients: a pilot study

A. Forrest, A. Corbett, C. Sykes, 2013, HIV medicine.

Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study

M. Hudgens, J. Eron, D. Wohl, 2012, Antimicrobial Agents and Chemotherapy.